share_log

Vertex Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Vertex Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

福泰製藥 | 10-Q：2024財年二季報
美股SEC公告 ·  08/03 04:06

Moomoo AI 已提取核心訊息

Vertex Pharmaceuticals reported a 6% increase in net product revenues to $2.6 billion in Q2 2024 compared to $2.5 billion in Q2 2023, driven by the U.S. launch of TRIKAFTA for children and strong uptake in ex-U.S. markets. Total R&D and SG&A expenses rose to $1.3 billion in Q2 2024 from $1.0 billion in Q2 2023, largely due to the acquisition of Alpine Immune Sciences. The company's cash and equivalents decreased to $4.6 billion at the end of the period from $10.4 billion at the beginning, primarily due to the Alpine acquisition. Vertex continues to focus on cystic fibrosis (CF) treatments, with four approved medicines and a pipeline including programs in CF, sickle cell disease, beta thalassemia, and pain management. The company is preparing for near-term launches of new products in CF and acute pain. Vertex's future plans include advancing its diversified pipeline, with a focus on transformative medicines for serious diseases, and investing in research and development to balance the risks inherent in product development.
Vertex Pharmaceuticals reported a 6% increase in net product revenues to $2.6 billion in Q2 2024 compared to $2.5 billion in Q2 2023, driven by the U.S. launch of TRIKAFTA for children and strong uptake in ex-U.S. markets. Total R&D and SG&A expenses rose to $1.3 billion in Q2 2024 from $1.0 billion in Q2 2023, largely due to the acquisition of Alpine Immune Sciences. The company's cash and equivalents decreased to $4.6 billion at the end of the period from $10.4 billion at the beginning, primarily due to the Alpine acquisition. Vertex continues to focus on cystic fibrosis (CF) treatments, with four approved medicines and a pipeline including programs in CF, sickle cell disease, beta thalassemia, and pain management. The company is preparing for near-term launches of new products in CF and acute pain. Vertex's future plans include advancing its diversified pipeline, with a focus on transformative medicines for serious diseases, and investing in research and development to balance the risks inherent in product development.
福泰製藥Q2 2024年淨產品收入同比增長6%，達到26億美元，而2023年Q2則爲25億美元，主要由於TRIKAFTA兒童用藥在美國上市和海外市場表現強勁所帶來的推動。研發和銷售費用從2023年Q2的10億美元增至2024年Q2的13億美元，主要是由於對alpine immune的收購所致。該公司現金及現金等價物從期初的104億美元下降至期末的46億美元，主要是由於alpine收購。 Vertex繼續專注於囊性纖維化（CF）治療，並擁有四種獲批藥物以及包括CF、鐮狀細胞貧血、β地中海貧血和疼痛管理計劃在內的一系列項目。該公司正在爲CF和急性疼痛的新產品近期上市做準備。Vertex的未來計劃包括推動其多樣化的項目線，並將重點放在治療嚴重疾病的革命性藥品上，並投資於研究和開發，以平衡產品開發所固有的風險。
福泰製藥Q2 2024年淨產品收入同比增長6%，達到26億美元，而2023年Q2則爲25億美元，主要由於TRIKAFTA兒童用藥在美國上市和海外市場表現強勁所帶來的推動。研發和銷售費用從2023年Q2的10億美元增至2024年Q2的13億美元，主要是由於對alpine immune的收購所致。該公司現金及現金等價物從期初的104億美元下降至期末的46億美元，主要是由於alpine收購。 Vertex繼續專注於囊性纖維化（CF）治療，並擁有四種獲批藥物以及包括CF、鐮狀細胞貧血、β地中海貧血和疼痛管理計劃在內的一系列項目。該公司正在爲CF和急性疼痛的新產品近期上市做準備。Vertex的未來計劃包括推動其多樣化的項目線，並將重點放在治療嚴重疾病的革命性藥品上，並投資於研究和開發，以平衡產品開發所固有的風險。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間